Kenalog
ApprovedSmall molecule
Kenalog is one of 124 small molecule programs targeting Aphthous Ulcer. It is currently in Approved.
5
Indications
14
Total Trials
1
Active Trials
123
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Kenalog
MMichael Khazzam
Approved
Epidiolex
Jazz PharmaceuticalsPreclinical
Toradol
RochePreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Bayer Aspirin
BayerPreclinical
Cataflam
NovartisPreclinical
Enbrel
IImmunex
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Effectiveness2 trials
Chronic Pelvic Pain1 trial
Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain
Completed·—·N/A·NCT02369068·21 enrolled
7 more indications
Age-Related Macular Degeneration1 trial
Aphthous Ulcer1 trial
Efficacy of Thyme Honey in The Management of Oral Aphthous Ulcers
Not yet recruiting·—·N/A·NCT06421038·20 enrolled
Shoulder pain1 trial
Granulation Tissue1 trial
Lateral Epicondylitis1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Kenalog. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMichael Khazzam